Survival of patients with advanced metastatic melanoma: The impact of novel therapies

European Journal of Cancer

Volumn 53, Issue , 2016, Pages 125-134

  Ugurel, Selma ^a   Röhmel, Joachim ^b   Ascierto, Paolo A ^c   Flaherty, Keith T ^d   Grob, Jean Jacques ^e   Hauschild, Axel ^f   Larkin, James ^g   Long, Georgina V ^h   Lorigan, Paul ⁱ   McArthur, Grant A ^j,k   Ribas, Antoni ^l   Robert, Caroline ^m   Schadendorf, Dirk ^a   Garbe, Claus ⁿ  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Fondazione G Pascale ^*  (Germany)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e AIX MARSEILLE UNIVERSITY   (France)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

Immune checkpoint blockers; Kinase inhibitors; Melanoma; Survival; Therapy

Indexed keywords

B RAF KINASE INHIBITOR; COBIMETINIB; DABRAFENIB; ENCORAFENIB; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; DISEASE COURSE; HUMAN; KAPLAN MEIER METHOD; LONG TERM SURVIVAL; METASTATIC MELANOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; EXPERIMENTAL THERAPY; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; KAPLAN-MEIER ESTIMATE; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS; THERAPIES, INVESTIGATIONAL;

EID: 84950283840     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.09.013     Document Type: Review

References (26)

1. T.K. Eigentler, U.M. Caroli, P. Radny, and C. Garbe Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials Lancet Oncol 4 2003 748 759
2. A.M. Eggermont, A. Spatz, and C. Robert Cutaneous melanoma Lancet 383 2014 816 827
3. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
4. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, M. Millward, and et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
5. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, and et al. Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2012 107 114
6. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, J. Sosman, and et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
7. C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz, D. Stroiakovski, and et al. Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 2015 30 39
8. G.V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, and et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N Engl J Med 371 2014 1877 1888
9. J. Larkin, P.A. Ascierto, B. Dreno, V. Atkinson, G. Liszkay, M. Maio, and et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 2014 1867 1876
10. D. Schadendorf, F.S. Hodi, C. Robert, J.S. Weber, K. Margolin, O. Hamid, and et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma J Clin Oncol 33 2015 1889 1894
11. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
12. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
13. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
14. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, and et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
15. C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, R. Kefford, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 2014 1109 1117
16. M.K.B. Parmar, and D. Machin Survival analysis - a practical approach 1995 Wiley & Sons New York
17. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
18. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, J.S. Weber, and et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
19. G.A. McArthur, P.B. Chapman, C. Robert, J. Larkin, J.B. Haanen, R. Dummer, and et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Lancet Oncol 15 2014 323 332
20. P.A. Ascierto, D. Minor, A. Ribas, C. Lebbe, A. O'Hagan, N. Arya, and et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma J Clin Oncol 31 2013 3205 3211
21. G.V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, and et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Lancet 386 2015 444 451
22. A. Ribas, R. Kefford, M.A. Marshall, C.J. Punt, J.B. Haanen, M. Marmol, and et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol 31 2013 616 622
23. C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
24. C. Robert, J. Schachter, G.V. Long, A. Arance, J.J. Grob, L. Mortier, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2015 2521 2532
25. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 2015 23 34
26. M.A. Postow, J. Chesney, A.C. Pavlick, C. Robert, K. Grossmann, D. McDermott, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2015 2006 2017